514 related articles for article (PubMed ID: 26559637)
1. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
Ashida K; Sakurai Y; Hori T; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Iwakiri K
Aliment Pharmacol Ther; 2016 Jan; 43(2):240-51. PubMed ID: 26559637
[TBL] [Abstract][Full Text] [Related]
2. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
[TBL] [Abstract][Full Text] [Related]
3. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.
Ashida K; Sakurai Y; Nishimura A; Kudou K; Hiramatsu N; Umegaki E; Iwakiri K; Chiba T
Aliment Pharmacol Ther; 2015 Sep; 42(6):685-95. PubMed ID: 26201312
[TBL] [Abstract][Full Text] [Related]
4. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
Xiao Y; Zhang S; Dai N; Fei G; Goh KL; Chun HJ; Sheu BS; Chong CF; Funao N; Zhou W; Chen M
Gut; 2020 Feb; 69(2):224-230. PubMed ID: 31409606
[TBL] [Abstract][Full Text] [Related]
5. Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial.
Xiao Y; Qian J; Zhang S; Dai N; Chun HJ; Chiu C; Chong CF; Funao N; Sakurai Y; Eisner JD; Xie L; Chen M
Chin Med J (Engl); 2024 Apr; 137(8):962-971. PubMed ID: 38654422
[TBL] [Abstract][Full Text] [Related]
6. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Miwa H; Uedo N; Watari J; Mori Y; Sakurai Y; Takanami Y; Nishimura A; Tatsumi T; Sakaki N
Aliment Pharmacol Ther; 2017 Jan; 45(2):240-252. PubMed ID: 27891632
[TBL] [Abstract][Full Text] [Related]
7. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
Oshima T; Arai E; Taki M; Kondo T; Tomita T; Fukui H; Watari J; Miwa H
Aliment Pharmacol Ther; 2019 Jan; 49(2):140-146. PubMed ID: 30589965
[TBL] [Abstract][Full Text] [Related]
8. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Mizokami Y; Oda K; Funao N; Nishimura A; Soen S; Kawai T; Ashida K; Sugano K
Gut; 2018 Jun; 67(6):1042-1051. PubMed ID: 28988197
[TBL] [Abstract][Full Text] [Related]
9. Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis.
Haruma K; Kinoshita Y; Yao T; Kushima R; Akiyama J; Aoyama N; Kanoo T; Miyata K; Kusumoto N; Uemura N
BMC Gastroenterol; 2023 May; 23(1):139. PubMed ID: 37127558
[TBL] [Abstract][Full Text] [Related]
10. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
Laine L; DeVault K; Katz P; Mitev S; Lowe J; Hunt B; Spechler S
Gastroenterology; 2023 Jan; 164(1):61-71. PubMed ID: 36228734
[TBL] [Abstract][Full Text] [Related]
11. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Kawai T; Oda K; Funao N; Nishimura A; Matsumoto Y; Mizokami Y; Ashida K; Sugano K
Gut; 2018 Jun; 67(6):1033-1041. PubMed ID: 29196436
[TBL] [Abstract][Full Text] [Related]
12. Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials.
Chandan S; Deliwala S; Mohan BP; Ramai D; Dhindsa B; Bapaye J; Kassab LL; Chandan OC; Facciorusso A; Adler DG
Indian J Gastroenterol; 2023 Aug; 42(4):475-484. PubMed ID: 37418052
[TBL] [Abstract][Full Text] [Related]
13. Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis.
Cho YK; Kim JH; Kim HS; Kim TO; Oh JH; Choi SC; Moon JS; Lee SK; Jung SW; Kim SS; Jung HK; Lee SP; Cheon GJ; Park MI; Jung HY; Ko KH; Sung IK; Lee SH; Lee JY; Lee ST; Rhee PL; Kim N; Hong SJ; Kim HJ; Kim GH; Lee KJ; Kim SK; Shin WG; Lee OY
Aliment Pharmacol Ther; 2023 Jan; 57(1):72-80. PubMed ID: 36314172
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
Shinozaki S; Osawa H; Kobayashi Y; Sakamoto H; Hayashi Y; Miura Y; Kawarai Lefor A; Yamamoto H
Scand J Gastroenterol; 2018 Aug; 53(8):897-904. PubMed ID: 30056768
[TBL] [Abstract][Full Text] [Related]
15. Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta-analysis of randomized controlled trials.
Simadibrata DM; Lesmana E; Fass R
J Gastroenterol Hepatol; 2024 Feb; ():. PubMed ID: 38353152
[TBL] [Abstract][Full Text] [Related]
16. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis.
Lee KJ; Son BK; Kim GH; Jung HK; Jung HY; Chung IK; Sung IK; Kim JI; Kim JH; Lee JS; Kwon JG; Park JH; Huh KC; Park KS; Park MI; Kim N; Lee OY; Jee SR; Lee SK; Youn SJ; Kim SK; Lee ST; Hong SJ; Choi SC; Kim TN; Youn YH; Park HJ; Kang MJ; Park CH; Kim BT; Youn S; Song GS; Rhee PL
Aliment Pharmacol Ther; 2019 Apr; 49(7):864-872. PubMed ID: 30843245
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Effects of Vonoprazan and Lansoprazole for Treating Endoscopic Submucosal Dissection-Induced Artificial Ulcers.
Hirai A; Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Tominaga K; Tokioka S; Higuchi K
Dig Dis Sci; 2018 Apr; 63(4):974-981. PubMed ID: 29464587
[TBL] [Abstract][Full Text] [Related]
18. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
[TBL] [Abstract][Full Text] [Related]
19. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
[TBL] [Abstract][Full Text] [Related]
20. Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China.
Zhang Z; Bao Y; Cai L; Gu Y; Yang T; Li X
Clin Drug Investig; 2022 Oct; 42(10):839-851. PubMed ID: 35994227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]